南方科技大学知识苑(SUSTech KC): Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a

题名	Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a
作者	Tang，Shuzhi 1,5; Liu，Wenzhen 1,5; Pan，Xiaohong 1; Liu，Libin 3; Yang，Yongshuai4 ; Wang，Dong 1,5; Xu，Peng 1; Huang，Mingdong 2; Chen，Zhuo 1,5
通讯作者	Huang，Mingdong
发表日期	2020-04-01
DOI	10.1016/j.lfs.2020.117404
发表期刊	LIFE SCIENCES 影响因子和分区
ISSN	0024-3205
EISSN	1879-0631
卷号	246
摘要	Aims: The study aims to investigate the effect of plasminogen activator inhibitor 1 (PAI-1), a primary inhibitor of fibrinolytic process, on blood glucose in type 2 diabetes mellitus (T2DM) and its mechanism. Materials and methods: We developed a highly potent and highly specific PAI-1 inhibitor, named PAItrap3, based on the inactivated urokinase. Meanwhile, a single point mutation of PAItrap3 (i.e., PAItrapNC) was parallelly prepared as negative control. PAItrap3 was intravenously injected into type 2 diabetic (T2D) mice and its effect on metabolic system was evaluated by measuring the levels of blood glucose, PAI-1, and tumor necrosis factor alpha (TNF-α) in T2D mice. Key findings: PAItrap3 significantly reduced the high blood glucose level and PAI-1 level in streptozotocin-induced T2D mice. PAItrapNC did not have any hypoglycemic effect at all on T2D mice. Mechanistically, both PAI-1 and TNF-α levels were attenuated by the administration of PAItrap3. In addition, we observed that PAItrap3 reduced the amount of fat droplets in adipocytes. Significance: These findings provide clear evidence for PAI-1 to participate in inflammation and obesity mediated hyperglycemia, and open up a new prospect for the treatment of T2DM by PAI-1 inhibition.
关键词	Adipocytes Fasting blood glucose (FBG) Inflammation Plasminogen activator inhibitor 1 (PAI-1) Tumor necrosis factor alpha (TNF-α) Type 2 diabetic (T2D)
相关链接	[Scopus记录]
收录类别	SCI
语种	英语
学校署名	其他
资助项目	National Natural Science Foundation of China[31370737] ; National Natural Science Foundation of China[21708043] ; National Natural Science Foundation of China[81971983]
WOS研究方向	Research & Experimental Medicine ; Pharmacology & Pharmacy
WOS类目	Medicine, Research & Experimental ; Pharmacology & Pharmacy
WOS记录号	WOS:000519537200013
出版者	PERGAMON-ELSEVIER SCIENCE LTD
ESI学科分类	BIOLOGY & BIOCHEMISTRY
Scopus记录号	2-s2.0-85079274020
来源库	Scopus
引用统计	被引频次[WOS]：6
成果类型	期刊论文
条目标识符	http://sustech.caswiz.com/handle/2SGJ60CL/106330
专题	工学院_生物医学工程系
作者单位	1.State Key Laboratory of Structural Chemistry,Institute of Research on the Structure of Matter,Chinese Academy of Sciences,Fuzhou,350002,China 2.College of Chemistry,Fuzhou University,Fuzhou,350116,China 3.Union Hospital,Fujian Medical University,Fuzhou,350001,China 4.Department of Biomedical Engineering,Southern University of Science and Technology (SUSTech),Shenzhen,518055,China 5.University of Chinese Academy of Sciences,Beijing,100049,China
推荐引用方式 GB/T 7714	Tang，Shuzhi,Liu，Wenzhen,Pan，Xiaohong,et al. Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a[J]. LIFE SCIENCES,2020,246.
APA	Tang，Shuzhi.,Liu，Wenzhen.,Pan，Xiaohong.,Liu，Libin.,Yang，Yongshuai.,...&Chen，Zhuo.(2020).Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a.LIFE SCIENCES,246.
MLA	Tang，Shuzhi,et al."Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a".LIFE SCIENCES 246(2020).